{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T12:05:35Z","timestamp":1762085135908,"version":"build-2065373602"},"reference-count":97,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017325","name":"Engineering Research Centers","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-CA-241762-01"],"award-info":[{"award-number":["R01-CA-241762-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007311","name":"Cleveland Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007311","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"European Research Council","doi-asserted-by":"publisher","award":["864815"],"award-info":[{"award-number":["864815"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1053\/j.seminhematol.2023.01.002","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T21:10:11Z","timestamp":1675804211000},"page":"25-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Challenges and opportunities of CAR T-cell therapies for CLL"],"prefix":"10.1053","volume":"60","author":[{"given":"Ziran","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Gr\u00e9goire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunho","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7677-537X","authenticated-orcid":false,"given":"Jan Joseph","family":"Melenhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.seminhematol.2023.01.002_bib0001","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann Oncol"},{"issue":"5-6","key":"10.1053\/j.seminhematol.2023.01.002_bib0002","first-page":"467","article-title":"Allogeneic bone marrow transplantation in chronic lymphocytic leukemia: report from the European Cooperative Group for bone marrow transplantation (8 cases)","volume":"30","author":"Michallet","year":"1988","journal-title":"Nouv Rev Fr Hematol (1978)"},{"issue":"4","key":"10.1053\/j.seminhematol.2023.01.002_bib0003","first-page":"275","article-title":"Allogeneic bone marrow transplantation in chronic lymphocytic leukemia: 17 cases","volume":"7","author":"Michallet","year":"1991","journal-title":"Rep EBMTG, Bone Marrow Transpl"},{"issue":"3","key":"10.1053\/j.seminhematol.2023.01.002_bib0004","doi-asserted-by":"crossref","first-page":"311","DOI":"10.7326\/0003-4819-124-3-199602010-00005","article-title":"HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry","volume":"124","author":"Michallet","year":"1996","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1053\/j.seminhematol.2023.01.002_bib0005","first-page":"669","article-title":"Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia","volume":"18","author":"Rondon","year":"1996","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"10.1053\/j.seminhematol.2023.01.002_bib0006","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/sj.bmt.1700850","article-title":"Induction of graft-versus-leukemia effect in a patient with chronic lymphocytic leukemia","volume":"20","author":"deMagalhaes-Silverman","year":"1997","journal-title":"Bone Marrow Transpl"},{"issue":"16","key":"10.1053\/j.seminhematol.2023.01.002_bib0007","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1200\/JCO.2005.04.569","article-title":"Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia","volume":"23","author":"Sorror","year":"2005","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2023.01.002_bib0008","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1200\/JCO.1998.16.8.2817","article-title":"Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1053\/j.seminhematol.2023.01.002_bib0009","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood.V98.13.3595","article-title":"Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality","volume":"98","author":"Khouri","year":"2001","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2023.01.002_bib0010","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.3324\/haematol.2019.239566","article-title":"Efficacy of minimal residual disease driven immune-intervention after allogeneic hematopoietic stem cell transplantation for high-risk chronic lymphocytic leukemia: results of a prospective multicenter trial","volume":"106","author":"Tournilhac","year":"2021","journal-title":"Haematological"},{"issue":"16","key":"10.1053\/j.seminhematol.2023.01.002_bib0011","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1182\/bloodadvances.2020001956","article-title":"Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents","volume":"4","author":"Roeker","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"10.1053\/j.seminhematol.2023.01.002_bib0012","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.bbmt.2016.09.013","article-title":"Clinical practice recommendations for use of allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia on behalf of the guidelines committee of the american society for blood and marrow transplantation","volume":"22","author":"Kharfan-Dabaja","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"issue":"12","key":"10.1053\/j.seminhematol.2023.01.002_bib0013","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1038\/sj.leu.2404838","article-title":"Characterization of graft-versus-leukemia responses in patients treated for advanced chronic lymphocytic leukemia with donor lymphocyte infusions after in vitro T-cell depleted allogeneic stem cell transplantation following reduced-intensity conditioning","volume":"21","author":"Hoogendoorn","year":"2007","journal-title":"Leukemia"},{"issue":"561","key":"10.1053\/j.seminhematol.2023.01.002_bib0014","doi-asserted-by":"crossref","first-page":"eabb7661","DOI":"10.1126\/scitranslmed.abb7661","article-title":"Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect","volume":"12","author":"Bachireddy","year":"2020","journal-title":"Sci Transl Med"},{"issue":"8","key":"10.1053\/j.seminhematol.2023.01.002_bib0015","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol Ther"},{"issue":"18","key":"10.1053\/j.seminhematol.2023.01.002_bib0016","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"issue":"303","key":"10.1053\/j.seminhematol.2023.01.002_bib0017","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"issue":"26","key":"10.1053\/j.seminhematol.2023.01.002_bib0018","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1053\/j.seminhematol.2023.01.002_bib0019","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1182\/blood.2021011895","article-title":"Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed\/refractory CLL or SLL","volume":"139","author":"Siddiqi","year":"2022","journal-title":"Blood"},{"issue":"25","key":"10.1053\/j.seminhematol.2023.01.002_bib0020","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1200\/JCO.19.03237","article-title":"Long-term outcomes from a randomized dose optimization study of chimeric antigen receptor modified T cells in relapsed chronic lymphocytic leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2023.01.002_bib0021","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/j.ymthe.2018.05.018","article-title":"Autologous CD19-targeted CAR T-cells in patients with residual CLL following initial purine analog-based therapy","volume":"26","author":"Geyer","year":"2018","journal-title":"Mol Ther"},{"issue":"9","key":"10.1053\/j.seminhematol.2023.01.002_bib0022","doi-asserted-by":"crossref","first-page":"e122627","DOI":"10.1172\/jci.insight.122627","article-title":"Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T-cells for relapsed\/refractory CLL","volume":"5","author":"Geyer","year":"2019","journal-title":"JCI Insight"},{"issue":"7897","key":"10.1053\/j.seminhematol.2023.01.002_bib0023","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T-cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2023.01.002_bib0024","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor\u2013modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"issue":"95","key":"10.1053\/j.seminhematol.2023.01.002_bib0025","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1053\/j.seminhematol.2023.01.002_bib0026","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"issue":"11","key":"10.1053\/j.seminhematol.2023.01.002_bib0027","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/ni.2431","article-title":"Cytokines of the \u03b3(c) family control CD4+ T cell differentiation and function","volume":"13","author":"Yamane","year":"2012","journal-title":"Nat Immunol"},{"issue":"5","key":"10.1053\/j.seminhematol.2023.01.002_bib0028","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.seminhematol.2023.01.002_bib0029","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen\u2013specific CAR T-cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Investig"},{"issue":"9","key":"10.1053\/j.seminhematol.2023.01.002_bib0030","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T-cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nature Med"},{"issue":"26","key":"10.1053\/j.seminhematol.2023.01.002_bib0031","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2023.01.002_bib0032","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1172\/JCI130144","article-title":"CD19-targeting CAR T-cell immunotherapy outcomes correlate with genomic modification by vector integration","volume":"130","author":"Nobles","year":"2020","journal-title":"J Clin Invest"},{"issue":"23","key":"10.1053\/j.seminhematol.2023.01.002_bib0033","first-page":"2569","article-title":"Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights","volume":"130","author":"Obstfeld","year":"2017","journal-title":"Blood, J Am Soc Hematol"},{"issue":"2","key":"10.1053\/j.seminhematol.2023.01.002_bib0034","doi-asserted-by":"crossref","first-page":"778","DOI":"10.4049\/jimmunol.178.2.778","article-title":"Chemokine-guided CD4+ T cell help enhances generation of IL-6RalphahighIL-7Ralpha high prememory CD8+ T cells","volume":"178","author":"Castellino","year":"2007","journal-title":"J Immunol"},{"issue":"5","key":"10.1053\/j.seminhematol.2023.01.002_bib0035","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.immuni.2010.05.003","article-title":"Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis","volume":"32","author":"Durant","year":"2010","journal-title":"Immunity"},{"key":"10.1053\/j.seminhematol.2023.01.002_bib0036","doi-asserted-by":"crossref","first-page":"e01949","DOI":"10.7554\/eLife.01949","article-title":"T cell-intrinsic role of IL-6 signaling in primary and memory responses","volume":"3","author":"Nish","year":"2014","journal-title":"Elife"},{"issue":"11","key":"10.1053\/j.seminhematol.2023.01.002_bib0037","doi-asserted-by":"crossref","first-page":"6356","DOI":"10.4049\/jimmunol.167.11.6356","article-title":"Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity","volume":"167","author":"Liu","year":"2001","journal-title":"J Immunol"},{"issue":"3","key":"10.1053\/j.seminhematol.2023.01.002_bib0038","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/00002371-200305000-00003","article-title":"Interleukin-2\u2013independent proliferation of human melanoma-reactive T lymphocytes transduced with an exogenous IL-2 gene is stimulation dependent","volume":"26","author":"Liu","year":"2003","journal-title":"J Immunotherapy (Hagerstown, Md.: 1997)"},{"issue":"11","key":"10.1053\/j.seminhematol.2023.01.002_bib0039","doi-asserted-by":"crossref","first-page":"7226","DOI":"10.4049\/jimmunol.175.11.7226","article-title":"Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine","volume":"175","author":"Hsu","year":"2005","journal-title":"J Immunol"},{"issue":"9","key":"10.1053\/j.seminhematol.2023.01.002_bib0040","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/2767-9764.CRC-22-0200","article-title":"Enhanced costimulatory signaling improves CAR T-cell effector responses in CLL","volume":"2","author":"Collins","year":"2022","journal-title":"Cancer Res Commun"},{"issue":"3","key":"10.1053\/j.seminhematol.2023.01.002_bib0041","doi-asserted-by":"crossref","first-page":"901","DOI":"10.4049\/jimmunol.1403189","article-title":"TLR-9 and IL-15 synergy promotes the in vitro clonal expansion of chronic lymphocytic leukemia B cells","volume":"195","author":"Mongini","year":"2015","journal-title":"J Immunol"},{"issue":"8","key":"10.1053\/j.seminhematol.2023.01.002_bib0042","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1182\/blood.V87.8.3327.bloodjournal8783327","article-title":"Interleukin-15 promotes the growth of leukemic cells of patients with B-cell chronic lymphoproliferative disorders","volume":"87","author":"Trentin","year":"1996","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2023.01.002_bib0043","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1084\/jem.160.5.1450","article-title":"Expression of interleukin 2 receptors on activated human B cells","volume":"160","author":"Waldmann","year":"1984","journal-title":"J Exp Med"},{"issue":"13","key":"10.1053\/j.seminhematol.2023.01.002_bib0044","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","article-title":"Augmentation of antitumor immunity by human and mouse CAR T-cells secreting IL-18","volume":"20","author":"Hu","year":"2017","journal-title":"Cell Rep"},{"issue":"7","key":"10.1053\/j.seminhematol.2023.01.002_bib0045","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1172\/JCI24176","article-title":"Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells","volume":"115","author":"G\u00f6rg\u00fcn","year":"2005","journal-title":"J Clin Investig"},{"issue":"7","key":"10.1053\/j.seminhematol.2023.01.002_bib0046","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J Clin Investig"},{"issue":"7","key":"10.1053\/j.seminhematol.2023.01.002_bib0047","first-page":"1412","article-title":"Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer","volume":"120","author":"Ramsay","year":"2012","journal-title":"Blood, J Am Soc Hematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2023.01.002_bib0048","first-page":"717","article-title":"CMV-specific CD8+ T-cell function is not impaired in chronic lymphocytic leukemia","volume":"123","author":"te Raa","year":"2014","journal-title":"Blood, J Am Soc Hematol"},{"issue":"2","key":"10.1053\/j.seminhematol.2023.01.002_bib0049","first-page":"203","article-title":"PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia","volume":"126","author":"McClanahan","year":"2015","journal-title":"Blood, J Am Soc Hematol"},{"issue":"26","key":"10.1053\/j.seminhematol.2023.01.002_bib0050","first-page":"3419","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood, J Am Soc Hematol"},{"issue":"8","key":"10.1053\/j.seminhematol.2023.01.002_bib0051","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nature Rev Immunol"},{"issue":"6","key":"10.1053\/j.seminhematol.2023.01.002_bib0052","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1182\/blood.V93.6.1992.406k23_1992_2002","article-title":"CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells","volume":"93","author":"Buhmann","year":"1999","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2023.01.002_bib0053","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1182\/blood-2005-03-1214","article-title":"Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules","volume":"106","author":"Palena","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2023.01.002_bib0054","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00262-008-0611-5","article-title":"Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients","volume":"58","author":"Litzinger","year":"2009","journal-title":"Cancer Immunol, Immunotherapy"},{"issue":"1","key":"10.1053\/j.seminhematol.2023.01.002_bib0055","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1038\/s41467-018-07136-7","article-title":"Structure of the 4-1BB\/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab","volume":"9","author":"Chin","year":"2018","journal-title":"Nat Commun"},{"issue":"9","key":"10.1053\/j.seminhematol.2023.01.002_bib0056","doi-asserted-by":"crossref","first-page":"E2068","DOI":"10.1073\/pnas.1716266115","article-title":"Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity","volume":"115","author":"Davenport","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"697","key":"10.1053\/j.seminhematol.2023.01.002_bib0057","doi-asserted-by":"crossref","first-page":"eabe2606","DOI":"10.1126\/scisignal.abe2606","article-title":"Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function","volume":"14","author":"Salter","year":"2021","journal-title":"Sci Signal"},{"issue":"6","key":"10.1053\/j.seminhematol.2023.01.002_bib0058","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.4049\/jimmunol.1502464","article-title":"Suppression of Glut1 and glucose metabolism by decreased Akt\/mTORC1 signaling drives T cell impairment in B Cell leukemia","volume":"197","author":"Siska","year":"2016","journal-title":"J Immunol"},{"issue":"1","key":"10.1053\/j.seminhematol.2023.01.002_bib0059","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood.2018885863","article-title":"Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8(+) T cells and impede CAR T-cell efficacy","volume":"134","author":"van Bruggen","year":"2019","journal-title":"Blood"},{"issue":"7709","key":"10.1053\/j.seminhematol.2023.01.002_bib0060","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"issue":"4","key":"10.1053\/j.seminhematol.2023.01.002_bib0061","doi-asserted-by":"crossref","first-page":"e149856","DOI":"10.1172\/JCI149856","article-title":"Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia","volume":"132","author":"Guan","year":"2022","journal-title":"J Clin Investig"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2023.01.002_bib0062","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1182\/blood-2022-159517","article-title":"Functional disruption of TET2-mediated cytosine oxidation in CAR T-cells using IDH1 neomorph","volume":"140","author":"Chung","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2023.01.002_bib0063","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1038\/emm.2017.5","article-title":"TET family dioxygenases and DNA demethylation in stem cells and cancers","volume":"49","author":"An","year":"2017","journal-title":"Exp Mol Med"},{"issue":"9","key":"10.1053\/j.seminhematol.2023.01.002_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110079","article-title":"CD19-CAR T-cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia","volume":"37","author":"Zebley","year":"2021","journal-title":"Cell Rep"},{"issue":"3","key":"10.1053\/j.seminhematol.2023.01.002_bib0065","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.immuni.2011.06.015","article-title":"Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells","volume":"35","author":"Youngblood","year":"2011","journal-title":"Immunity"},{"issue":"7685","key":"10.1053\/j.seminhematol.2023.01.002_bib0066","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nature24633","article-title":"Origin and differentiation of human memory CD8 T cells after vaccination","volume":"552","author":"Akondy","year":"2017","journal-title":"Nature"},{"issue":"4","key":"10.1053\/j.seminhematol.2023.01.002_bib0067","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.immuni.2017.03.012","article-title":"Polycomb repressive complex 2-mediated chromatin repression guides effector CD8","volume":"46","author":"Gray","year":"2017","journal-title":"Immunity"},{"issue":"620","key":"10.1053\/j.seminhematol.2023.01.002_bib0068","doi-asserted-by":"crossref","first-page":"eabh0272","DOI":"10.1126\/scitranslmed.abh0272","article-title":"Deleting DNMT3A in CAR T-cells prevents exhaustion and enhances antitumor activity","volume":"13","author":"Prinzing","year":"2021","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2023.01.002_bib0069","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","article-title":"Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency","volume":"25","author":"Feucht","year":"2019","journal-title":"Nat Med"},{"issue":"8","key":"10.1053\/j.seminhematol.2023.01.002_bib0070","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.it.2020.06.008","article-title":"Rewriting history: epigenetic reprogramming of CD8","volume":"41","author":"Zebley","year":"2020","journal-title":"Trends Immunol"},{"issue":"6","key":"10.1053\/j.seminhematol.2023.01.002_bib0071","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.4049\/jimmunol.1301395","article-title":"Global DNA methylation remodeling accompanies CD8 T cell effector function","volume":"191","author":"Scharer","year":"2013","journal-title":"J Immunol"},{"issue":"6316","key":"10.1053\/j.seminhematol.2023.01.002_bib0072","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.aaf2807","article-title":"Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade","volume":"354","author":"Pauken","year":"2016","journal-title":"Science"},{"issue":"15","key":"10.1053\/j.seminhematol.2023.01.002_bib0073","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/bloodadvances.2019000219","article-title":"Clonal expansion of CAR T-cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy","volume":"3","author":"Shah","year":"2019","journal-title":"Blood advances"},{"issue":"76","key":"10.1053\/j.seminhematol.2023.01.002_bib0074","doi-asserted-by":"crossref","first-page":"pe38","DOI":"10.1126\/scisignal.276pe38","article-title":"Activation of T cells: releasing the brakes by proteolytic elimination of Cbl-b","volume":"2","author":"Schmitz","year":"2009","journal-title":"Science signaling"},{"issue":"1","key":"10.1053\/j.seminhematol.2023.01.002_bib0075","doi-asserted-by":"crossref","first-page":"e001688","DOI":"10.1136\/jitc-2020-001688","article-title":"Deletion of Cbl-b inhibits CD8(+) T-cell exhaustion and promotes CAR T-cell function","volume":"9","author":"Kumar","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1053\/j.seminhematol.2023.01.002_bib0076","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1182\/blood-2006-08-044156","article-title":"Retroviral vector insertion sites associated with dominant hematopoietic clones mark \"stemness\" pathways","volume":"109","author":"Kustikova","year":"2007","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2023.01.002_bib0077","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J Clin Invest"},{"issue":"22","key":"10.1053\/j.seminhematol.2023.01.002_bib0078","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1182\/blood-2009-12-257352","article-title":"Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial","volume":"115","author":"Wang","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2023.01.002_bib0079","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1053\/j.seminhematol.2023.01.002_bib0080","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1056\/NEJMoa1000164","article-title":"Efficacy of gene therapy for X-linked severe combined immunodeficiency","volume":"363","author":"Hacein-Bey-Abina","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2023.01.002_bib0081","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2023.01.002_bib0082","article-title":"Favorable activity and safety profile of memory-enriched CD19-targeted chimeric antigen receptor T Cell therapy in adults with high-risk relapsed\/refractory ALL","author":"Aldoss","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1053\/j.seminhematol.2023.01.002_bib0083","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.4049\/jimmunol.1402262","article-title":"Cutting edge: identification of autoreactive CD4+ and CD8+ T cell subsets resistant to PD-1 pathway blockade","volume":"194","author":"Pauken","year":"2015","journal-title":"J Immunol"},{"issue":"12","key":"10.1053\/j.seminhematol.2023.01.002_bib0084","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1172\/JCI96610","article-title":"CD84 regulates PD-1\/PD-L1 expression and function in chronic lymphocytic leukemia","volume":"128","author":"Lewinsky","year":"2018","journal-title":"J Clin Invest"},{"issue":"7718","key":"10.1053\/j.seminhematol.2023.01.002_bib0085","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","article-title":"Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response","volume":"560","author":"Chen","year":"2018","journal-title":"Nature"},{"issue":"4","key":"10.1053\/j.seminhematol.2023.01.002_bib0086","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.ymthe.2020.12.033","article-title":"Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia","volume":"29","author":"Cox","year":"2021","journal-title":"Mol Ther"},{"issue":"5","key":"10.1053\/j.seminhematol.2023.01.002_bib0087","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/bloodadvances.2018028720","article-title":"Pharmacologic control of CAR T-cell function using dasatinib","volume":"3","author":"Weber","year":"2019","journal-title":"Blood Adv"},{"issue":"7","key":"10.1053\/j.seminhematol.2023.01.002_bib0088","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.ccell.2022.06.001","article-title":"Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence","volume":"40","author":"Belk","year":"2022","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1053\/j.seminhematol.2023.01.002_bib0089","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13045-022-01255-x","article-title":"Rewiring mitochondrial metabolism to counteract exhaustion of CAR T-cells","volume":"15","author":"Huang","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2023.01.002_bib0090","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nature Med"},{"key":"10.1053\/j.seminhematol.2023.01.002_bib0091","first-page":"7364","article-title":"Co-stimulation of CD28\/CD40 signaling molecule potentiates CD19CAR T-cell functions and stemness","author":"Khopanlert","year":"2022","journal-title":"Blood 140(Supplement 1)"},{"issue":"2","key":"10.1053\/j.seminhematol.2023.01.002_bib0092","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T-cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"issue":"4","key":"10.1053\/j.seminhematol.2023.01.002_bib0093","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1084\/jem.20171068","article-title":"4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses","volume":"215","author":"Menk","year":"2018","journal-title":"J Exp Med"},{"issue":"5","key":"10.1053\/j.seminhematol.2023.01.002_bib0094","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.cmet.2022.03.013","article-title":"The mitochondrial pyruvate carrier regulates memory T cell differentiation and antitumor function","volume":"34","author":"Wenes","year":"2022","journal-title":"Cell Metabo"},{"issue":"12","key":"10.1053\/j.seminhematol.2023.01.002_bib0095","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapyalternative splicing of CD19 enables resistance to CART-19","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer disc"},{"issue":"10","key":"10.1053\/j.seminhematol.2023.01.002_bib0096","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nature Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2023.01.002_bib0097","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nature Commun"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719632300001X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719632300001X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:28:25Z","timestamp":1758522505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003719632300001X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S003719632300001X"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2023.01.002","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges and opportunities of CAR T-cell therapies for CLL","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2023.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}